Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
got a dose of Menveo reconstituted with normal saline; got a dose of Menveo reconstituted with normal saline; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On 18-JUN-2025, the patient received Menveo. On 18-JUN-2025, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: got a dose of Menveo reconstituted with normal saline) and inappropriate dose of vaccine administered (Verbatim: got a dose of Menveo reconstituted with normal saline). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date: 18-JUN-2025 The healthcare professional had called to request data regarding the validity and need for revaccination of a patient who had received a dose of Menveo reconstituted with normal saline which led to, wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. They declined to provide information about the vaccine, patient, and event, and did not consent to follow-up. The vaccine administration facility was the same as the primary reporter.